Relevant bibliographies by topics / Antibacterial agents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Antibacterial agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antibacterial agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antibacterial agents"

Bremner, John B. "Some approaches to new antibacterial agents." Pure and Applied Chemistry 79, no. 12 (January 1, 2007): 2143–53. http://dx.doi.org/10.1351/pac200779122143.

Full text

Abstract:

Bacteria use a number of resistance mechanisms to counter the antibacterial challenge, and one of these is the expression of transmembrane protein-based efflux pumps which can pump out antibacterials from within the cells, thus lowering the antibacterial concentration to nonlethal levels. For example, in S. aureus, the NorA pump can pump out the antibacterial alkaloid berberine and ciprofloxacin. One general strategy to reduce the health threat of resistant bacteria is to block a major bacterial resistance mechanism at the same time as interfering with another bacterial pathway or target site. New developments of this approach in the context of dual-action prodrugs and dual-action (or hybrid) drugs in which one action is targeted at blocking the NorA efflux pump and the second action at an alternative bacterial target site (or sites) for the antibacterial action are discussed. The compounds are based on a combination of 2-aryl-5-nitro-1H-indole derivatives (as the NorA efflux pump blocking component) and derivatives of berberine. General design principles, syntheses, antibacterial testing, and preliminary work on modes of action studies are discussed.

APA, Harvard, Vancouver, ISO, and other styles

Verma, Tarawanti, and Nitin Bansal. "Triazinone Derivatives as Antibacterial and Antimalarial Agents." Asian Pacific Journal of Health Sciences 6, no. 2 (June 2019): 1–20. http://dx.doi.org/10.21276/apjhs.2019.6.2.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kaye, Elaine T., and Kenneth M. Kaye. "TOPICAL ANTIBACTERIAL AGENTS." Infectious Disease Clinics of North America 9, no. 3 (September 1995): 547–59. http://dx.doi.org/10.1016/s0891-5520(20)30685-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Thorsteinsson, T., T. Loftsson, and M. Masson. "Soft Antibacterial Agents." Current Medicinal Chemistry 10, no. 13 (July 1, 2003): 1129–36. http://dx.doi.org/10.2174/0929867033457520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Brickner, Steven J. "Oxazolidinone Antibacterial Agents." Current Pharmaceutical Design 2, no. 2 (April 1996): 175–94. http://dx.doi.org/10.2174/1381612802666220921173820.

Full text

Abstract:

The oxazolidinones are a new class of synthetic antibacterial agents. These compounds demonstrate potent in vitro and in vivo activity against important human pathogens, including multiple antibiotic-resistant strains of gram positive organisms including the staphylococci, streptococci, and enterococci. The oxazolidinones have a novel mechanism of action, inhibiting bacterial protein synthesis at a very early step prior to initiation. Literature disclosures have described the inability to detect in vitro bacterial resistance development to the oxazolidinones. Only the (S)-enantiomer is active; a new synthetic route yielding oxazolidinones with high optical purity has been reported. This paper will review the spectrum of activity, mechanism of action studies, toxicity issues, and structure activity relationships of the oxazolidinones.

APA, Harvard, Vancouver, ISO, and other styles

Telford, Mark. "Releasing antibacterial agents." Materials Today 7, no. 12 (December 2004): 10. http://dx.doi.org/10.1016/s1369-7021(04)00613-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Hussar, Daniel A. "New Antibacterial Agents." American Pharmacy 33, no. 1 (January 1993): 41–46. http://dx.doi.org/10.1016/s0160-3450(15)30889-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kaye, Elaine T. "TOPICAL ANTIBACTERIAL AGENTS." Infectious Disease Clinics of North America 14, no. 2 (June 2000): 321–39. http://dx.doi.org/10.1016/s0891-5520(05)70250-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Lio, Peter A., and Elaine T. Kaye. "Topical Antibacterial Agents." Medical Clinics of North America 95, no. 4 (July 2011): 703–21. http://dx.doi.org/10.1016/j.mcna.2011.03.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Lio, Peter A., and Elaine T. Kaye. "Topical antibacterial agents." Infectious Disease Clinics of North America 18, no. 3 (September 2004): 717–33. http://dx.doi.org/10.1016/j.idc.2004.04.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Antibacterial agents"

Zhang, Huichun. "Metal oxide-facilitated oxidation of antibacterial agents." Diss., Available online, Georgia Institute of Technology, 2004:, 2004. http://etd.gatech.edu/theses/available/etd-07072004-152317/unrestricted/zhang%5Fhuichun%5F200407%5Fphd.pdf.

Full text

Abstract:

Thesis (Ph. D.)--School of Civil and Environmental Engineering, Georgia Institute of Technology, 2005. Directed by Ching-Hua Huang.
Wine, Paul, Committee Member ; Pavlostathis, Spyros, Committee Member ; Mulholland, James, Committee Member ; Yiacoumi, Sotira, Committee Member ; Huang, Ching-Hua, Committee Chair. Includes bibliographical references.

APA, Harvard, Vancouver, ISO, and other styles

Tan, Jinlong. "Design and Synthesis of Novel Antibacterial Agents." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/25809.

Full text

Abstract:

The latest data on antimicrobial resistance (AMR) related mortality is alarming. A conservative estimate places current global death due to AMR infections at 700,000 annually and projections anticipate that this could rise to 10 million by 2050. Over 50 major initiatives have emerged from the European Union (EU), United Kingdom (UK) and the United States of America (US) since 2007 aimed at improving surveillance, stewardship, and refreshing the drug development pipeline. The identification of priority pathogens, such as the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens has also assisted in directing global attention and efforts towards developing agents against these dangerous microbes. However, despite the FDA approval of 17 new antimicrobial agents since 2013, no novel class of Gram negative active agents has been introduced. Concerning the antibacterials in the drug development pipeline which are currently in phase 3 development or near obtaining approval (fourteen), only one (cefiderocol, a cephalosporin derivative) displays broad activity against priority Gram negative pathogens whilst seven display very specific activity against the same – none of these are new classes. Fragment-based drug discovery (FBDD) is an efficient strategy to utilise in this research. FBDD involves virtual screening of exceptionally small ligands, termed fragments, against the crystal structure of the target protein. Fragments are known to sample chemical space more efficiently than conventional virtual screening ligand libraries. Fragment hits may have low affinity initially but demonstrate a good amount of free energy of binding per heavy atom, referred to as ligand efficiency. It is then necessary to optimise the best scoring fragments by introducing structural modifications to improve affinity and pharmacokinetic properties towards more drug-like leads. Chapter 2 of this thesis details the design of novel Extended Spectrum β-lactamase (ESBL) inhibitors through FBDD. This begins with a discussion regarding the benefits and rationale of virtual screening, followed by details of the software and methods used by the candidate to generate drug-like small molecules against protein crystal structures of the target carbapenemase, New Delhi Metallo-β-lactamase 1 (NDM-1). Careful and rational optimisation of high scoring fragments resulted in a structurally diverse set of lead compounds with anticipated ability to restore carbapenem activity in pathogenic bacterial which express NDM-1. Furthermore, we aimed to synthesise a structural extension of lead compounds to provide a prodrug form which we hypothesised could improve effectiveness of the lead compound in Gram negative bacteria. Previously published bacteria detection and identification research by the Groundwater research group targeted an aminopeptidase widely distributed in Gram negative bacteria for differentiating between Gram negative and Gram positive species from clinical isolates. This enzyme, L-alanyl aminopeptidase, cleaved chromogenic compounds containing a terminal L-alanine amino acid residue, which released the chromophore and produced colouration of the colony. Therefore, these ‘L-alanyl precursors’ allowed for distinction between Gram positive and Gram negative bacteria in clinical isolates. We proposed that L-alanyl derivatives of the lead compounds could produce the same effect, effectively targeting the antibacterial agents towards Gram negative species, which are of greater clinical urgency. The compounds which were successfully synthesised were tested by international collaborators and, separately, by the candidate against two clinically important Gram negative pathogens. Inhibition of the target carbapenemase was determined by observed improvement of carbapenem MIC (in this case meropenem) and, therefore, required testing of the synthesised inhibitors in tandem with the carbapenem, by simultaneous broth microdilution. All synthesised compounds displayed the ability to improve meropenem MIC by at least two-fold (that is, the MIC of meropenem halved in the presence of a test inhibitor) and demonstrated no growth inhibition in the absence of meropenem at the concentrations tested. Particularly noteworthy was the performance of L-proline-based compounds, derived from fragment 1, which displayed impressive activity. The thiol-containing L-proline derivative 8 was able to improve the MIC of meropenem by sixteen-fold (i.e. from 64 µg/mL to 4 µg/mL). The L-alanyl prodrug forms of the lead compounds also, generally, demonstrated greater potency than their respective parent lead compounds. In the case of one pair, the prodrug form was seven-times more effective than the corresponding lead compound. Chapter 3 of this thesis details the use of rational structure modification to generate improved antibacterials based on agents discovered by previous PhD candidates (Dr Liao and Dr Lin) within the research group. The target of this work was Filamenting temperature-sensitive mutant Z (FtsZ), an enzyme ubiquitous in bacteria which is critical for successful cell division and replication. FtsZ inhibitors are a validated antibacterial target, with one such inhibitor, TXA707 and its prodrug TXA709, currently in Phase 1 clinical trials. Research by Dr Liao and Dr Lin identified curcumin-based compounds 88 and 89 respectively which were successful antibacterial agents in Bacillus subtilis, a Gram positive species. The work described in Chapter 3 of this thesis aimed to introduce structural modifications to these compounds to produce less chemically reactive derivatives which retained, or, ideally, improved antibacterial activity. This resulted in the phenolic derivatives which demonstrated comparable activity against B. subtilis. However, these compounds demonstrated no significant activity against a Gram negative species of bacteria, Escherichia coli. Consequently, an L-alanyl prodrug form of the lead phenol 94 was vehemently pursued. In summary, this thesis details the exploration of a diverse range of synthetic reactions which produced structurally diverse potential antibacterial agents. Many of these compounds exhibited encouraging antimicrobial activity, either by inhibiting a resistance-conferring enzyme (NDM-1) or by inhibiting an enzyme critical for bacterial division (FtsZ).

APA, Harvard, Vancouver, ISO, and other styles

Marshall, Neil J. "Antibacterial agents designed to exploit peptide transport systems." Thesis, Bangor University, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.262012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Penishkevich, Ya. "Ophthalmic topical antibacterial agents: current and evolving options." Thesis, БДМУ, 2020. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/18146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Smith, Nichola Ann. "Photoactivatable Ru(II) polypyridyl complexes as antibacterial agents." Thesis, University of Warwick, 2015. http://wrap.warwick.ac.uk/76173/.

Full text

Abstract:

Novel photoactive ruthenium(II) complexes were designed to incorporate existing anti-tuberculosis drugs, isoniazid and nicotinamide, that could be released from the ruthenium(II) cage by photoactivation with visible light. Two sets of complexes were synthesised based on cis-[Ru(N-N')2(L)2][PF6]2and cis-[Ru(N-N')2(L)X][PF6], where N-N' is 2,2'-bipyridine (bpy) or 1,10-phenanthroline (phen), L is isoniazid (INH) or nicotinamide (NA) and X is either Cl or I. Their dynamic behaviour in solution was explored using NMR to probe the presence of atropisomers. In the case of cis-[Ru(bpy)2(NA)Cl][PF6] (1) and cis-[Ru(bpy)2(NA)I][PF6] (2), the rotation of NA is hindered on the NMR timescale at room temperature, behaviour that was surprisingly not observed for cis-[Ru(bpy)2(NA)2][PF6]2 (5). The hindered rotation was explored by computational methods (DFT) and revealed that hydrogen bonding between the halide and protons of the NA ligand hindered the rotation. The photochemical properties of the Ru(II) complexes were explored by UV-visible spectroscopy and liquid chromatography. All cis-[Ru(N-N')2(L)2][PF6]2complexes in aqueous solution release one ligand, L, in under 1 min using a blue LED (λirr = 463 nm, 50 mW cm- 2 ) to form the photoproduct cis-[Ru(N-N')2(L)(H2O)] 2+ . Continued photoirradiation releases a second ligand, L, with the production of various Ru(II) and Ru(III) aqua photoproducts (with both cis and trans geometry). Interestingly their production was dependent on the power of the light source. Complementary computational studies (DFT/TD-DFT) were utilised to understand structure-activity relationships with respect to photoactivity. The results from the calculations suggest that the number of key electronic transitions (notably1 MLCT) and the favourable leaving properties of the ligand, L, influence the rate of photorelease. In the latter case, a stronger p-accepting leaving ligand shifts the dissociative 3 MC state to lower energy, thus promoting more efficient ligand release. The photobiological properties of the Ru(II) complexes were explored by investigating binding to biomolecules and screening their antibacterial activity in vitro. The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) binds to the nucleobase 9-ethylguanine (9-EtG) after photoirradiation with a blue LED to produce cis-[Ru(bpy)2(INH)(9-EtG)] 2+ , however reaction with the amino acid L-cysteine was not observed. A 96-array blue LED (λirr = 465 nm, 20 mW cm-2 ) and 32-array multi-coloured LED (λirr = 465 nm, 520 nm, 589 nm and 625 nm, 5 mW cm-2 ) were designed in-house to screen the activity of the complexes in vitro. Their design and construction is described in detail. When tested against Mycobacterium smegmatis (a model for Mycobacterium tuberculosis), complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (6) showed the greatest activity upon photoirradiation for 1 min with a blue LED, with at least a 3x increase in potency when compared to the ligand alone, INH. Most importantly the complexes are inactive in the dark, showing that the antibacterial ligand is selectively released in vitro after photoirradiation. The complex cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9), where MOPEP is 4-[2-(4-methoxyphenyl)ethynyl]pyridine, was initially designed to study two-photon activation via a femtosecond-pulsed laser. Surprisingly the complex was one-photon active with 600 nm and 800 nm light, due to the MOPEP ligand extending and increasing the intensity of the one-photon absorption band shoulder in the 600-800 nm region.

APA, Harvard, Vancouver, ISO, and other styles

Nielsen, Elisabet I. "Pharmacometric Models for Antibacterial Agents to Improve Dosing Strategies." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-144909.

Full text

Abstract:

Antibiotics are among the most commonly prescribed drugs. Although the majority of these drugs were developed several decades ago, optimal dosage (dose, dosing interval and treatment duration) have still not been well defined. This thesis focuses on the development and evaluation of pharmacometric models that can be used as tools in the establishment of improved dosing strategies for novel and already clinically available antibacterial drugs. Infectious diseases are common causes of death in preterm and term newborn infants. A population pharmacokinetic (PK) model for gentamicin was developed based on data from a prospective study. Body-weight and age (gestational and post-natal age) were found to be major factors contributing to variability in gentamicin clearance and therefore important patient characteristics to consider for improved dosing regimens. A semi-mechanistic pharmacokinetic-pharmacodynamic (PKPD) model was also developed, to characterize in vitro bacterial growth and killing kinetics following exposure to six antibacterial drugs, representing a broad selection of mechanisms of action and PK as well as PD characteristics. The model performed well in describing a wide range of static and dynamic drug exposures and was easily applied to other bacterial strains and antibiotics. It is, therefore, likely to find application in early drug development programs. Dosing of antibiotics is usually based on summary endpoints such as the PK/PD indices. Predictions based on the PKPD model showed that the commonly used PK/PD indices were well identified for all investigated drugs, supporting that models based on in vitro data can be predictive of antibacterial effects observed in vivo. However, the PK/PD indices were sensitive to the study conditions and were not always consistent between patient populations. The PK/PD indices may therefore extrapolate poorly across sub-populations. A semi-mechanistic modeling approach, utilizing the type of models described here, may thus have higher predictive value in a dose optimization tailored to specific patient populations.

APA, Harvard, Vancouver, ISO, and other styles

Das, Sanjan Kumar. "Application of Structural Genomics for Developing Novel Antibacterial Agents." Thesis, University of Sheffield, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.486462.

Full text

Abstract:

The structure-based design of novel antibiotics has great potentiaL To achieve this goal the first step is to gather structural information on relevant proteins and utilise this to find inhibitors through a process of screening and subsequent optimising using structural data. In thisÃ‚Â· pilot study a number of essential gene products from Bacillus subtilis were targeted for structural studies where homologues were present in pathogenic microorganisms. In the initial analysis 41 essential genes of unknown structure or function were selected for structure determination. From this list 9 genes were rejected as their protein products were assigned as possible membrane proteins by hydropathy analysis. From the remaining 32 genes on the list 12 (ysxC, thiD, ywaF, ydiC, ydiE, yrrA, yabH, ylxR, yqiB, yacN, ymjL and luxS) were selected for study as part of this thesis. Recombinant DNA technology was used to produce pure protein for crystallisation trials and subsequent structure determination by X-ray crystallography. Successful overexpression was achieved for 8 of the protein targets ofwhich 7 were found to be soluble. 6 ofthese were taken forward for crystallisation as part of this work with the 7th beingÃ‚Â·pursued by another member of the laboratory due to project overlap. Of these 6 proteins 5 were successfully purified and crystallised (LuxS, YsxC, YacN, YabH, and ThiD) and structures were determined for all but ThiD. The successful crystallisation of all of the 5 soluble proteins was unexpected and maybe related to the characteristics of the structure determination pipeline which requires the expression of the protein product in a soluble form and at high leveL This may result in the selection of proteins with a higher tendency to crystallise. The gene to structure conversion rate'obtained here (33%) is equivalent to that obtained for the overall programme on all 32 genes (34%) suggesting that 4 bacterial proteins 1/3rd of the proteome can be analysed as part of a structural genomics programme.

APA, Harvard, Vancouver, ISO, and other styles

Griffiths, Jennifer Mary. "Model systems to investigate bacterial persistence to antibacterial agents." Thesis, University of Leeds, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.590484.

Full text

Abstract:

Bacterial persistence describes the phenotypic variation displayed by clonal bacterial populations which permits a small fraction of cells to survive exposure to antimicrobials. The phenomenon was first described in the 19405 by Joseph Bigger who observed that penicillin could not sterilize a culture of Staphylococcus aureus. The surviving cells were not resistant mutants as they displayed equal susceptibility to penicillin as the parent population upon subculture. Among the various hypotheses which have been proposed to explain this phenomenon, the majority consider persisters to be dormant The prevailing model in Escherichia coli is that this behaviour results from stochastic expression of the toxic portion of chromosomal toxin-antitoxin modules. However, the exact mechanisms underlying this behaviour remain elusive, partly owing to the apparent redundancy of this phenotype. Persistence has been observed in all bacterial species tested to date however, most studies have focused on E. coli. This study aimed to explore the mechanisms of persistence in S. aureus by characterising two transposon insertion mutants identified as being defective in persistence to antimicrobials. The mutants were affected in different ABC transporter-like proteins, AbcA and PapA. The role of ABC transporters in persistence was further evaluated by independently inactivating abcA and papA. The resulting strains exhibited a reduced-persister phenotype to antimicrobials from different classes supporting a role for AbcA and PapA in S. aureus perSistence. The second part of this study sought to investigate the use of mycoplasmae as model systems for investigating persistence. Time-kill studies established that Mycoplasma hominis and Mycoplasma galliseptcium do generate persister cells. As neither organism has toxin-antitoxin modules in their genomes, the results imply that other mechanisms for persistence must exist. These mechanisms were investigated by generating and screening a M, gallisepticum transposon insertion library for genes involved in persistence. Four mutants with reduced persistence, disrupted in spoT, vlhA 1.04, asnA and MGA_0126, were identified.

APA, Harvard, Vancouver, ISO, and other styles

Carraco, Moreira Joao Bruno. "Characterisation of symmetric bis-benzimidazoles as antibacterial chemotherapeutic agents." Thesis, University of London, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.579712.

Full text

Abstract:

Nosocomial and community-acquired infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria are associated with high levels of mortality, morbidity and significant social and economic costs in the U.K. and elsewhere. As the evolution of multi-drug resistance relentlessly erodes the utility of currently available antibacterial drugs, it is essential to maintain efforts to search for new classes of antibacterial agents. Benzimidazoles are potent antihelmintic agents discovered in 1961. Chemical modifications led to the synthesis of the head-to-tail fluorochrome Hoechst 33258 and, more recently, to symmetric head-to-head bis-benzimidazoles (sBBZ). The antibacterial potential of these compounds was examined. Antibacterial activity was evaluated by minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays using a total of 143 Gram-positive isolates, including 61 MRSA, 12 vancomycin resistant enterococci (VRE), 12 Streptococcus pneumoniae, 11 Listeria monocytogenes, 7 Mycobacterium spp. (including Mycobacterium tuberculosis) and 14 Gram-negative isolates. Structure-activity relationships were determined and key requirements for activity were identified. Acute toxicity of sBBZs was assessed using the sulforhodamine B staining method and a zebrafish embryo model. To clarify mode of action, time kill studies, flow cytometry, DNA microarrays and radioisotope incorporation assays were employed. sBBZs displayed activity against Gram-positive but not Gram-negative pathogens; the most potent compound possessed MIC90 values of 0.06, 0.125 and 1 mg/L against, respectively, MRSA, VRE and M tuberculosis isolates. Data suggests that sBBZs are bacteriostatic agents that interfere primarily with the DNA machinery and do not select for drug resistant variants over a 31-day period of drug exposure. Subtle structural modifications have an incisive effect on in vitro potency of sBBZs. Toxicity was determined as minimal for WI-38 cell line and the zebrafish embryo model of infection. Sub-inhibitory concentrations of sBBZs inhibited MRSA transcription of pathogenicity-associated genes. Symmetric bis-benzimidazoles are new DNA-interfering bacteriostatic agents with potent antibacterial activity and significant therapeutic potential against Gram-positive bacteria, including MRSA and M tuberculosis.

APA, Harvard, Vancouver, ISO, and other styles

Lam, Chi-wah. "Antibacterial effects of nanoparticles on cariogenic organisms /." View the Table of Contents & Abstract, 2005. http://sunzi.lib.hku.hk/hkuto/record/B31490414.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Antibacterial agents"

Anderson, Rosaleen J., Paul W. Groundwater, Adam Todd, and Alan J. Worsley. Antibacterial Agents. Chichester, UK: John Wiley & Sons, Ltd, 2012. http://dx.doi.org/10.1002/9781118325421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dax, Scott L. Antibacterial Chemotherapeutic Agents. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-009-0097-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dax, Scott L. Chemotherapeutic antibacterial agents. New York: Chapman & Hall, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Mascaretti, Oreste A. Bacteria versus Antibacterial Agents. Washington, DC, USA: ASM Press, 2003. http://dx.doi.org/10.1128/9781555817794.

Full text

APA, Harvard, Vancouver, ISO, and other styles

M, Shafer William, ed. Antibacterial peptide protocols. Totowa, N.J: Humana Press, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Dax, Scott L. Chemotherapeutic antibacterialagents. New York: Chapman & Hall, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Amyes, Sebastian G. B. Antibacterial chemotherapy: Theory, problems and practice. Oxford: Oxford University Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

-D, Busse W., Zeiler H. J. 1947-, Labischinski H. 1948-, and Metzger Karl-Georg 1929-, eds. Antibacterial therapy: Achievements, problems, and future perspectives. Berlin: Springer-Verlag, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Frost & Sullivan., ed. The U.S. market for antibacterial and antiviral agents. New York (106 Fulton St., New York 10038): Frost & Sullivan, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

United States. Environmental Protection Agency. Office of Pesticide Programs. Special Review and Reregistration Division, ed. Reregistration eligibility document (RED): M-cresol and xylenol, list D, cases 4027 and 4098. [Washington, D.C.]: Environmental Protection Agency, Office of Pesticide Programs, Special Review and Reregistration Division, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Antibacterial agents"

Souli, Maria, and Helen Giamarellou. "Antibacterial Agents." In European Handbook of Dermatological Treatments, 1345–59. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-45139-7_131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Rhee, Douglas J., Kathryn A. Colby, Lucia Sobrin, and Christopher J. Rapuano. "Antibacterial Agents." In Ophthalmologic Drug Guide, 1–30. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-7621-5_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Ōiwa, Ruiko. "Antibacterial Agents." In The Search for Bioactive Compounds from Microorganisms, 1–29. New York, NY: Springer New York, 1992. http://dx.doi.org/10.1007/978-1-4612-4412-7_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kern, Winfried V. "Antibacterial Agents." In Infections in Hematology, 229–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-44000-1_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Giamarellou, H., and M. Souli. "Antibacterial agents." In European Handbook of Dermatological Treatments, 687–99. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-662-07131-1_121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Lewis, James S., and Karen Bush. "Antibacterial Agents." In Manual of Clinical Microbiology, 1169–211. Washington, DC, USA: ASM Press, 2015. http://dx.doi.org/10.1128/9781555817381.ch68.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Souli, Maria, Garyfalia Poulakou, and Helen Giamarellou. "Antibacterial Agents." In European Handbook of Dermatological Treatments, 1527–42. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-15130-9_134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dax, Scott L. "Peptidic antibacterial agents." In Antibacterial Chemotherapeutic Agents, 346–66. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-009-0097-4_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dax, Scott L. "Miscellaneous antibacterial agents." In Antibacterial Chemotherapeutic Agents, 367–84. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-009-0097-4_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dax, Scott L. "Introduction." In Antibacterial Chemotherapeutic Agents, 1–37. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-009-0097-4_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antibacterial agents"

Gutierrez, Margarita, Yorley Duarte, Barbara Arevalo, Gonzalo Martinez, Francisca Matus, Tomas Poblete, Jessica Amigo, Gabriel Vallejos, and Luis Astudillo. "NITROGEN HETEROCYCLES AS POTENTIAL ANTIBACTERIAL AGENTS." In The 17th International Electronic Conference on Synthetic Organic Chemistry. Basel, Switzerland: MDPI, 2013. http://dx.doi.org/10.3390/ecsoc-17-a035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dhilna, C. R., S. M. Gopinath, A. M. Sajith, B. Savitha, S. D. Shruthi, and Muthipeedika Nibin Joy. "Some imidazolyl benzamides as potent antibacterial agents." In PROCEEDINGS OF INTERNATIONAL CONFERENCE ON RECENT TRENDS IN MECHANICAL AND MATERIALS ENGINEERING: ICRTMME 2019. AIP Publishing, 2020. http://dx.doi.org/10.1063/5.0018039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Mirolyubova, Tatyana V., Lyudmila V. Redina, and Igor A. Chmutin. "Obtaining and investigating the effectiveness of masterbatches with various antibacterial agents." In INTERNATIONAL SCIENTIFIC-TECHNICAL SYMPOSIUM (ISTS) «IMPROVING ENERGY AND RESOURCE-EFFICIENT AND ENVIRONMENTAL SAFETY OF PROCESSES AND DEVICES IN CHEMICAL AND RELATED INDUSTRIES». The Kosygin State University of Russia, 2021. http://dx.doi.org/10.37816/eeste-2021-2-222-224.

Full text

Abstract:

Some features of obtaining masterbatches with antibacterial agents for the production of polypropylene non-woven spunbond material used for medical masks and dressing gowns are considered, and the results of an experimental study of the effectiveness of the obtained masterbatches for antibacterial activity in laboratory conditions are presented.

APA, Harvard, Vancouver, ISO, and other styles

Starly, Binil, Shih-Feng Lan, and David Schmidtke. "Customized Release of Metronidazole From Composite Casted Rings of Poly-Caprolactone/Alginate for Periodontal Drug Delivery." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14177.

Full text

Abstract:

Dental implants provide support for dental crowns and bridges by serving as abutments for the replacement of missing teeth. The objective of this study was to demonstrate a novel method of controlled localized delivery of antibacterial agents to an implant site using a custom fabricated ring. The study involved incorporating a model antibacterial agent (metronidazole) into custom designed Poly-ε-Caprolactone/Alginate (PCL/Alginate) composite rings to produce the intended controlled release profile. In vitro release studies indicate that pure (100%) alginate rings exhibited an expected burst release of metronidazole in the first few hours, whereas Alginate/PCL composite rings produced a medium burst release followed by a sustained release for a period greater than 4 weeks. By varying the PCL/Alginate weight ratios, we have shown that we can control the amount of antibacterial agents released to provide the minimal inhibitory concentration needed for adequate protection. The developed system demonstrates a controllable drug release profile and the potential for the ring to inhibit bacterial biofilm growth for the prevention of diseases such as peri-implantitis resulting from bacterial infection at the implant site.

APA, Harvard, Vancouver, ISO, and other styles

Syahri, J., Suwantono, H. Nasution, B. A. Nurohmah, and Emmy Yuanita. "QSAR study on fluoroquinolone derivatives as potential antibacterial agents." In THE 8TH INTERNATIONAL CONFERENCE OF THE INDONESIAN CHEMICAL SOCIETY (ICICS) 2019. AIP Publishing, 2020. http://dx.doi.org/10.1063/5.0001076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Neryr, Tatiana Barreto Rocha, and Marcelo Pinheiro Fontes. "ANALYSIS OF APPLICATION OF ANTIBACTERIAL AGENTS IN TEXTILES: SYSTEMATIC REVIEW." In VI Simpósio Internacional de Inovação e Tecnologia. São Paulo: Editora Blucher, 2020. http://dx.doi.org/10.5151/siintec2020-analysisofapplication.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Lopatenko, Dmitriy. "PATHOGENIC FLORA WITH PNEUMOEMPYEMA AND ITS SENSITIVITY TO ANTIBACTERIAL AGENTS." In MODALITĂȚI CONCEPTUALE DE DEZVOLTARE A ȘTIINȚEI MODERNE. European Scientific Platform, 2020. http://dx.doi.org/10.36074/20.11.2020.v2.22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Lopatenko, Dmitriy. "PATHOGENIC FLORA WITH PNEUMOEMPYEMA AND ITS SENSITIVITY TO ANTIBACTERIAL AGENTS." In The results of scientific mind's development: 2019. 유럽과학플랫폼, 2019. http://dx.doi.org/10.36074/22.12.2019.v1.36.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Amalina, Ilma, Ni Nyoman Tri Puspaningsih, and Hery Suwito. "In Silico analysis of pyrimidine derivatives as potential antibacterial agents." In PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGY AND MULTIDISCIPLINE (ICATAM) 2021: “Advanced Technology and Multidisciplinary Prospective Towards Bright Future” Faculty of Advanced Technology and Multidiscipline. AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0121466.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Matos, Maria, Saleta Vazquez-Rodriguez, Cristina Fuentes-Edfuf, Ysabel Santos, Angeles Muñoz-Crego, Eugenio Uriarte, and Lourdes Santana. "Synthesis of Novel Amino/Nitro Substituted 3-Arylcoumarins as Antibacterial Agents." In The 16th International Electronic Conference on Synthetic Organic Chemistry. Basel, Switzerland: MDPI, 2012. http://dx.doi.org/10.3390/ecsoc-16-01036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antibacterial agents"

Heijkenskjöld, Lolo. Articles treated with antibacterial agents. Nordic Council of Ministers, March 2014. http://dx.doi.org/10.6027/tn2014-513.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Pang, Yuan-Ping. Novel Small-Molecule Antibacterial Agents. Fort Belvoir, VA: Defense Technical Information Center, July 2014. http://dx.doi.org/10.21236/ada612221.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Cabrera, Anahi Maldonado, Blayra Maldonado Cabrera, Dalia Isabel Sánchez Machado, and Jaime López Cervantes. Wound healing therapeutic effect of chitosan nanofibers: a systematic review and meta- analysis of animal studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0121.

Full text

Abstract:

Review question / Objective: Review question: Does chitosan base nanofibers has significant wound healing therapeutics effects in animal models? A preclinical systematic review of intervention will be carried out to evaluate the therapeutic effects of chitosan nanofibers on animal skin lesions. The PICO (Population, Intervention, Comparator, Outcome) scheme will be used: Intervention: full-thickness skin lesions, and the application of chitosan nanofibers as treatment for animal skin lesions. Regardless of the concentration of chitosan or other added compounds used. Comparison: No intervention, topical placebo agents and standard skin lesions treatments will be included. Outcome: wound healing area, wound closure, type of wound closure (first, second or third intention), healing time, infectious processes (antibacterial/antifungal properties), blood loss (hemostatic properties) and adverse effects.

APA, Harvard, Vancouver, ISO, and other styles

Choudhary, Ruplal, Victor Rodov, Punit Kohli, John D. Haddock, and Samir Droby. Antimicrobial and antioxidant functionalized nanoparticles for enhancing food safety and quality: proof of concept. United States Department of Agriculture, September 2012. http://dx.doi.org/10.32747/2012.7597912.bard.

Full text

Abstract:

General concept. The reported 1-year study tested the feasibility ofpreparing antimicrobial and antioxidant nanoparticlesfunctionalized with natural phenolic compounds, as a first step to reach the ultimate goal - improving safely and quality of foods by developing novel antimicrobial and antioxidant food-contacting materials. The secondary objectives of the study were (a) selecting the most promising phenoliccompounds, (b) building nanoparticles with the selected phenolicgrafted on their Surface, and (c) testing antimicrobial and antioxidant properties of these particles. The study was expected to provide a " go/no go" decision as concerning the prospects of phenolic- bound nanoparticles as antimicrobial and antioxidant agents. Results. In course of the feasibility study, curucminwas chosen as the most promising phenoliccompound due to its high antibacterial activity exceeding other tested compounds by at leas one order of magnitude. Lipsome-typephospholipid/polydiacetylene(PDA) nanoparticlesfunctionalizedwith curcuminwere successfully built. The pitfall of limited curcumin amount that could be covalently bound to theparticle surface was circumvented by inclusion of curcunun in the liposome body. It was suggested onthe basis of fluorescence spectroscopy that curcuminwas bound by hydrophobic forces in the bi1ayer periphery of the Liposomesand therefore mightexert a contact effect on microorganisms. The curcumin functionalizednanoparticles(CFN) were shown to have a strong bactericidal activity towards both Gram-negative (E. coli) and Gram-positive (B. ce,·e11s) bacteria, but only limited effect against yeast. Furthermore, beyond the originallyplanned objectives, preliminary trials showed that CFN could be bound to silanized glass surface rendering aנבtiנnicrobial activity to the glass. Tnaddition, the particles showed antioxidantcapacity. Tberefore, it ,vas co11cluded tlוattlוeaims of tlוefeasibility study bad been successfully reached an

APA, Harvard, Vancouver, ISO, and other styles

Ficht, Thomas, Gary Splitter, Menachem Banai, and Menachem Davidson. Characterization of B. Melinensis REV 1 Attenuated Mutants. United States Department of Agriculture, December 2000. http://dx.doi.org/10.32747/2000.7580667.bard.

Full text

Abstract:

Brucella Mutagenesis (TAMU) The working hypothesis for this study was that survival of Brucella vaccines was directly related to their persistence in the host. This premise is based on previously published work detailing the survival of the currently employed vaccine strains S19 and Rev 1. The approach employed signature-tagged mutagenesis to construct mutants interrupted in individual genes, and the mouse model to identify mutants with attenuated virulence/survival. Intracellular survival in macrophages is the key to both reproductive disease in ruminants and reticuloendothelial disease observed in most other species. Therefore, the mouse model permitted selection of mutants of reduced intracellular survival that would limit their ability to cause reproductive disease in ruminants. Several classes of mutants were expected. Colonization/invasion requires gene products that enhance host-agent interaction or increase resistance to antibacterial activity in macrophages. The establishment of chronic infection requires gene products necessary for intracellular bacterial growth. Maintenance of chronic infection requires gene products that sustain a low-level metabolism during periods characterized little or no growth (1, 2). Of these mutants, the latter group was of greatest interest with regard to our originally stated premise. However, the results obtained do not necessarily support a simplistic model of vaccine efficacy, i.e., long-survival of vaccine strains provides better immunity. Our conclusion can only be that optimal vaccines will only be developed with a thorough understanding of host agent interaction, and will be preferable to the use of fortuitous isolates of unknown genetic background. Each mutant could be distinguished from among a group of mutants by PCR amplification of the signature tag (5). This approach permitted infection of mice with pools of different mutants (including the parental wild-type as a control) and identified 40 mutants with apparently defective survival characteristics that were tentatively assigned to three distinct classes or groups. Group I (n=13) contained organisms that exhibited reduced survival at two weeks post-infection. Organisms in this group were recovered at normal levels by eight weeks and were not studied further, since they may persist in the host. Group II (n=11) contained organisms that were reduced by 2 weeks post infection and remained at reduced levels at eight weeks post-infection. Group III (n=16) contained mutants that were normal at two weeks, but recovered at reduced levels at eight weeks. A subset of these mutants (n= 15) was confirmed to be attenuated in mixed infections (1:1) with the parental wild-type. One of these mutants was eliminated from consideration due to a reduced growth rate in vitro that may account for its apparent growth defect in the mouse model. Although the original plan involved construction of the mutant bank in B. melitensis Rev 1 the low transformability of this strain, prevented accumulation of the necessary number of mutants. In addition, the probability that Rev 1 already carries one genetic defect increases the likelihood that a second defect will severely compromise the survival of this organism. Once key genes have been identified, it is relatively easy to prepare the appropriate genetic constructs (knockouts) lacking these genes in B. melitensis Rev 1 or any other genetic background. The construction of "designer" vaccines is expected to improve immune protection resulting from minor sequence variation corresponding to geographically distinct isolates or to design vaccines for use in specific hosts. A.2 Mouse Model of Brucella Infection (UWISC) Interferon regulatory factor-1-deficient (IRF-1-/- mice have diverse immunodeficient phenotypes that are necessary for conferring proper immune protection to intracellular bacterial infection, such as a 90% reduction of CD8+ T cells, functionally impaired NK cells, as well as a deficiency in iNOS and IL-12p40 induction. Interestingly, IRF-1-/- mice infected with diverse Brucella abortus strains reacted differently in a death and survival manner depending on the dose of injection and the level of virulence. Notably, 50% of IRF-1-/- mice intraperitoneally infected with a sublethal dose in C57BL/6 mice, i.e., 5 x 105 CFU of virulent S2308 or the attenuated vaccine S19, died at 10 and 20 days post-infection, respectively. Interestingly, the same dose of RB51, an attenuated new vaccine strain, did not induce the death of IRF-1-/- mice for the 4 weeks of infection. IRF-1-/- mice infected with four more other genetically manipulated S2308 mutants at 5 x 105 CFU also reacted in a death or survival manner depending on the level of virulence. Splenic CFU from C57BL/6 mice infected with 5 x 105 CFU of S2308, S19, or RB51, as well as four different S2308 mutants supports the finding that reduced virulence correlates with survival Of IRF-1-/- mice. Therefore, these results suggest that IRF-1 regulation of multi-gene transcription plays a crucial role in controlling B. abortus infection, and IRF-1 mice could be used as an animal model to determine the degree of B. abortus virulence by examining death or survival. A3 Diagnostic Tests for Detection of B. melitensis Rev 1 (Kimron) In this project we developed an effective PCR tool that can distinguish between Rev1 field isolates and B. melitensis virulent field strains. This has allowed, for the first time, to monitor epidemiological outbreaks of Rev1 infection in vaccinated flocks and to clearly demonstrate horizontal transfer of the strain from vaccinated ewes to unvaccinated ones. Moreover, two human isolates were characterized as Rev1 isolates implying the risk of use of improperly controlled lots of the vaccine in the national campaign. Since atypical B. melitensis biotype 1 strains have been characterized in Israel, the PCR technique has unequivocally demonstrated that strain Rev1 has not diverted into a virulent mutant. In addition, we could demonstrate that very likely a new prototype biotype 1 strain has evolved in the Middle East compared to the classical strain 16M. All the Israeli field strains have been shown to differ from strain 16M in the PstI digestion profile of the omp2a gene sequence suggesting that the local strains were possibly developed as a separate branch of B. melitensis. Should this be confirmed these data suggest that the Rev1 vaccine may not be an optimal vaccine strain for the Israeli flocks as it shares the same omp2 PstI digestion profile as strain 16M.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!